Business Context and Reporting Period
This Form 8-K Current Report from Palatin Technologies, Inc. (PTN) covers events occurring on May 7 and May 8, 2025. The filing details a material definitive agreement for a registered public offering of securities and a significant corporate event involving the suspension of trading and delisting of the Company's common stock from the NYSE American.
Key Financial Metrics and Transaction Details
- Offering Structure: The Company entered into a securities purchase agreement to sell 76,666,667 shares of common stock at $0.15 per share, alongside Series F, G, and H common warrants.
- Warrant Terms:
- Series F: Exercise price $0.30; 5-year term.
- Series G: Exercise price $0.15; 24-month term or FDA Exercise Period.
- Series H: Exercise price $0.225; 24-month term (issued upon exercise of Series G).
- Proceeds: Expected gross proceeds were initially projected to yield $11.5 million net. However, due to investor withdrawals, the Company raised approximately $1.1 million in net proceeds on May 8, 2025.
- Use of Proceeds: Net proceeds are designated for general working capital purposes.
- Placement Fees: The Company agreed to pay placement agents a cash fee of 7.00% of gross proceeds plus reimbursement of legal fees up to $85,000.
Material Changes and Delisting Event
On May 7, 2025, NYSE Regulation suspended trading of Palatin Technologies' common stock and initiated delisting proceedings. The exchange determined the Company was no longer suitable for listing under Section 1003(f)(v) due to the low selling price of its stock. Additionally, the Company failed to regain compliance with Sections 1003(a)(i), (ii), and (iii) by the expiration of its 18-month compliance plan on April 10, 2025.
Consequently, trading began on the OTC Pink Market on May 8, 2025. The Company is assessing the viability of appealing the delisting determination.
Outlook, Risks, and Unusual Items
- Offering Reduction: Certain investors notified the Company on May 7, 2025, that they would not proceed to closing due to the trading suspension and delisting notice. This resulted in a significant reduction of the offering size and proceeds.
- Covenants: The Purchase Agreement includes a 45-day prohibition on selling additional securities and a 4-month prohibition on entering into variable rate transactions.
- Ownership Limitations: Holders are restricted from exercising warrants if it would result in ownership exceeding 9.99% (or 4.99% at option) of outstanding shares.
- Forward-Looking Risks: The Company highlights risks related to trading on the OTC Pink Market, the uncertainty of the delisting appeal, and the variability of expected net proceeds.
Investor Verification Checklist
- Verify the final closing amount and number of shares issued, as the initial target was significantly reduced to approximately $1.1 million in net proceeds.
- Confirm the current trading status and ticker symbol on the OTC Pink Market following the NYSE American delisting.
- Review the status of the Company's appeal to the Listings Qualifications Panel regarding the delisting decision.
- Assess the impact of the reduced capital raise on the Company's liquidity and ability to fund general working capital needs.
- Examine the specific terms of the Series G and H warrants, particularly the "FDA Exercise Period" condition for Series G expiration.